Marein

Marein

SCHEMBL620953

O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(O)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 1.00
TDP1 Q9NUW8 1/20 1.00
AKR1B1 P15121 1/20 0.63
DPP4 P27487 1/20 0.63
SNCA P37840 1/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
TERT O14746 1/20 0.53
CYP46A1 Q9Y6A2 3/20 0.53
PTGS1 P23219 1/20 0.49
ACHE P22303 1/20 0.49
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
PRKCA P17252 3/20 0.48
CDK5 Q00535 1/20 0.48
CDK5R1 Q15078 1/20 0.48
CYP19A1 P11511 1/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Marein SCHEMBL620954 1.00 GAA (1.00) GAATDP1AKR1B1DPP4SNCA
Marein SCHEMBL13227297 1.00 GAA (1.00) GAATDP1AKR1B1DPP4SNCA
Marein SCHEMBL13255955 1.00 GAA (1.00) GAATDP1AKR1B1DPP4SNCA
SCHEMBL19645122 0.91 GAA (0.83) GAATDP1AKR1B1DPP4SNCA
SCHEMBL29456135 0.90 GAA (0.81) GAATDP1AKR1B1DPP4SNCA
SCHEMBL25214813 0.86 AKR1B1 (0.80) GAATDP1AKR1B1DPP4SNCA
SCHEMBL30092342 0.86 AKR1B1 (0.80) GAATDP1AKR1B1DPP4SNCA
SCHEMBL25221633 0.86 AKR1B1 (0.80) GAATDP1AKR1B1DPP4SNCA
SCHEMBL30383483 0.86 AKR1B1 (0.80) GAATDP1AKR1B1DPP4SNCA
SCHEMBL30384234 0.86 AKR1B1 (0.80) GAATDP1AKR1B1DPP4SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4599048-A1 COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS Trailhead Biosystems Inc. (US) 2025-08-13 EP claimed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP claimed
EP-4569090-A2 METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS Trailhead Biosystems Inc. (US) 2025-06-18 EP claimed
US-20250144056-A1 ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) 2025-05-08 US claimed
WO-2025059442-A1 MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS REMOTE EPIGENETICS INC. (US) 2025-03-20 WO claimed
EP-4444870-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS Trailhead Biosystems Inc. (US) 2024-10-16 EP claimed
EP-4410284-A1 COMPOUND AND METHOD FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER Apteeus (FR) 2024-08-07 EP claimed
WO-2024063818-A9 METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. (US) 2024-05-23 WO claimed
US-20240117302-A1 COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS TRAILHEAD BIOSYSTEMS INC. 2024-04-11 US claimed
WO-2024076758-A1 COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS TRAILHEAD BIOSYSTEMS INC. (US) 2024-04-11 WO claimed
US-20120041078-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER SENOMYX, INC. (US) 2012-02-16 US claimed
CN-101611148-A Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin LIBRAGEN (FR) 2009-12-23 CN claimed
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives LIBRAGEN (FR) 2009-09-17 US claimed
EP-2027279-A2 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES Libragen (FR) 2009-02-25 EP claimed
WO-2007144368-A2 WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS LIBRAGEN (FR) 2007-12-21 WO claimed
CN-101069563-A Beverage composition and method for preventing degradation of vitamins in beverages PEPSICO INC (US) 2007-11-14 CN claimed
US-20070110851-A1 Beverage composition and method of preventing degradation of vitamins in beverages PEPSICO, INC. 2007-05-17 US claimed
EP-1782701-A1 Beverage composition and method of preventing degradation of vitamins in beverages PepsiCo, Inc. (US) 2007-05-09 EP claimed
US-20040091589-A1 Prevention of synthetic color fading in beverages using botanically derived color stabilizers PEPSICO, INC. 2004-05-13 US claimed
EP-0317453-B1 MEDICINAL COMPOSITIONS BASED ON FLAVONOIDS AND SAPONINS EXTRACTED FROM CHRYSANTHELLUM, PROCESS FOR THEIR MANUFACTURE AND THERAPEUTICAL USES IPHYM SA Société Anonyme dite : (FR) 1993-02-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041078-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER TFEB, TREH, SLC2A8 GAA 62/4885TDP1 3705/4885AKR1B1 4076/4885
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives UGGT1, TYR, LCT GAA 71/4885TDP1 910/4885AKR1B1 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.